Skip to main content

Table 2 Fas/Fas ligand pathway polymorphisms associated (p <0.05) with acute kidney injury (AKI) susceptibility in Caucasian subjects from the Fluid and Catheter Treatment Trial

From: Associations between single nucleotide polymorphisms in the FAS pathway and acute kidney injury

Gene

SNP

OR (95 % CI)a

P value

FDR-adjusted P value

MAF

NFKBIA

rs1050851

2.34 (1.58–3.46)

1.06 × 10−5

<0.003

0.18

NFKBIA

rs2233417

2.46 (1.61–3.76)

1.81 × 10−5

<0.003

0.15

CFLAR

rs12105811

0.51 (0.33–0.79)

0.002

0.18

0.25

NFKBIA

rs7157810

1.70 (1.15–2.51)

0.007

0.50

0.18

FASLG

rs5030772

1.80 (1.16–2.79)

0.007

0.41

0.11

BCL2L1

rs1484994

0.63 (0.44–0.91)

0.011

0.54

0.35

BCL2L1

rs6060621

0.65 (0.45–0.92)

0.015

0.60

0.35

TIRAP

rs1786697

0.60 (0.39–0.92)

0.017

0.60

0.23

RELA

rs10896027

1.49 (1.06–2.11)

0.022

0.69

0.34

MAP3K1

rs33330

0.64 (0.43–0.95)

0.024

0.69

0.34

NFKBIA

rs8904

0.67 (0.47–0.96)

0.027

0.69

0.41

CFLAR

rs4482462

0.65 (0.44–0.96)

0.028

0.67

0.27

NFKBIA

rs696

0.68 (0.48–0.96)

0.029

0.63

0.41

DAXX

rs2239839

1.50 (1.03–2.18)

0.032

0.65

0.26

CFLAR

rs6728771

0.66 (0.45–0.97)

0.034

0.64

0.27

MAP3K5

rs911179

0.70 (0.50–0.98)

0.037

0.66

0.48

CASP9

rs1862710

0.71 (0.51–0.99)

0.041

0.68

0.49

MYD88

rs6853

0.61 (0.38–1.00)

0.047

0.76

0.16

BCL2L1

rs6058381

0.53 (0.28–1.02)

0.048

0.72

0.09

TLR6

rs3821985

0.71 (0.50–1.00)

0.049

0.70

0.38

CFLAR

rs7583529

0.68 (0.46–1.00)

0.0497

0.67

0.26

MAP3K5

rs1570054

0.71 (0.50–1.00)

0.0498

0.64

0.40

  1. aRisk of AKI (stage 1 or above) with each additional copy of the minor allele. SNP single nucleotide polymorphism, OR odds ratio, FDR false discovery rate, MAF minor allele frequency